- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02252445
Propofol and Sevoflurane for Catheter-Related Bladder Discomfort
Effect of Propofol and Sevoflurane on Postoperative Catheter-Related Bladder Discomfort
Study Overview
Status
Intervention / Treatment
Detailed Description
The mechanism of catheter-related bladder discomfort is thought to be related to the muscarinic receptor. Propofol and desflurane are most widely used as an anesthetic agent. Propofol and desflurane are known to block the muscarinic receptor in different ways.
The investigators want to evaluate the efficacy of the propofol and sevoflurane for the prevention of catheter-related bladder discomfort.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- Seolu National University of Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients scheduled for transurethral bladder excision under general anesthesia
- ASA I-III
Exclusion Criteria:
- Foley catheter less than 18 Fr.
- Patients with obstruction of urinary tract
- Patients with neurogenic bladder
- Patients with severe obesity
- Patients with neurologic disorder
- Patients with chronic pain
- Patients with allergic history to propofol or sevoflurane
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Propofol
Propofol will be administered as the anesthetic maintenance agent.
|
Propofol will be administered.
|
|
Experimental: Sevoflurane
Sevoflurane will be administered as the anesthetic maintenance agent.
|
Sevoflurane will be administered.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Catheter-related Bladder Discomfort
Time Frame: 1 hour postoperatively
|
Catheter-related bladder discomfort will be measured at 1 hour postoperatively (0:none, 1:mild, 2:moderate, 3:severe).
Patients with score >0 will be counted.
|
1 hour postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Nausea
Time Frame: 0, 1, 6 and 24 hour postoperatively
|
Nausea will be measured at 0, 1, 6 and 24 hour postoperatively.
|
0, 1, 6 and 24 hour postoperatively
|
|
Vomiting
Time Frame: 0, 1, 6 and 24 hour postoperatively
|
Vomiting will be measured at 0, 1, 6 and 24 hour postoperatively.
|
0, 1, 6 and 24 hour postoperatively
|
|
Flushing
Time Frame: 0, 1, 6 and 24 hour postoperatively
|
Flushing will be measured at 0, 1, 6 and 24 hour postoperatively.
|
0, 1, 6 and 24 hour postoperatively
|
|
Dizziness
Time Frame: 0, 1, 6 and 24 hour postoperatively
|
Dizziness will be measured at 0, 1, 6 and 24 hour postoperatively.
|
0, 1, 6 and 24 hour postoperatively
|
|
Analgesics
Time Frame: 0, 1, 6 and 24 hour postoperatively
|
The amount of analgesics will be measured at 0, 1, 6 and 24 hour postoperatively.
|
0, 1, 6 and 24 hour postoperatively
|
|
Catheter-related Bladder Discomfort
Time Frame: 0, 6 and 24 hour postoperatively
|
Catheter-related bladder discomfort will be measured at 1 hour postoperatively (0:none, 1:mild, 2:moderate, 3:severe).
Patients with score >0 will be counted.
|
0, 6 and 24 hour postoperatively
|
|
Hemodynamic Parameters
Time Frame: 0, 1, 5, 10 minute postoperatively
|
Mean blood pressure and heart rate will be measured at 0, 1, 5, 10 minute postoperatively.
Measurement at 10 minute means Mean blood pressure and heart rate at the admission of post-anesthetic care unit.
|
0, 1, 5, 10 minute postoperatively
|
|
Dry Mouth
Time Frame: 0, 1, 6 and 24 hour postoperatively
|
Dry mouth will be measured at 0, 1, 6 and 24 hour postoperatively.
|
0, 1, 6 and 24 hour postoperatively
|
|
Blurred Vision
Time Frame: 0, 1, 6 and 24 hour postoperatively
|
Blurred vision will be measured at 0, 1, 6 and 24 hour postoperatively.
|
0, 1, 6 and 24 hour postoperatively
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Urologic Diseases
- Urinary Bladder Diseases
- Urinary Bladder Neoplasms
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Platelet Aggregation Inhibitors
- Hypnotics and Sedatives
- Anesthetics, Inhalation
- Propofol
- Sevoflurane
Other Study ID Numbers
- CRBDPPFSEVO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Bladder Neoplasms
-
Peking University First HospitalRecruitingUrinary Bladder Cancer | Bladder Cancer | Bladder Neoplasms | Bladder Tumors | Neoplasms, BladderChina
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Bristol-Myers SquibbRecruitingUrinary Bladder Cancer | Invasive Bladder CancerNetherlands
-
Memorial Sloan Kettering Cancer CenterPfizerCompletedBladder Cancer | Urinary BladderUnited States
-
Mansoura UniversityCompletedBladder Cancer | Bladder Disease | Bladder Neoplasm | Micro-RNAEgypt
-
GlaxoSmithKlineCompletedNeoplasms, Urinary BladderBelgium
-
UroGen Pharma Ltd.CompletedCarcinoma of Urinary Bladder, SuperficialIsrael, Spain, Italy, Switzerland
-
Medical University of ViennaUniversity of Turin, ItalyRecruitingT1 Urinary Bladder CancerAustria
-
Taris Biomedical LLCCompletedUrinary Bladder CancerNetherlands
-
Mansoura UniversityCompletedCarcinoma of Urinary Bladder, SuperficialEgypt
-
National University Hospital, SingaporeNational Medical Research Council (NMRC), SingaporeCompletedCarcinoma of Urinary Bladder, SuperficialSingapore
Clinical Trials on Propofol
-
Nurdan SağbaşActive, not recruitingMajor Depression | Bipolar Affective Disorder | Bipolar Depression Depressed PhaseTurkey (Türkiye)
-
Groupe Hospitalier Diaconesses Croix Saint-SimonCompletedOocyte Retrieval | Medically Assisted Procreation (MAP)France
-
Marmara University Pendik Training and Research...Not yet recruitingEndoscopic Submucosal Dissection | Respiratory Complications | Target Controlled Infusion of Propofol | Endoscopy Unit
-
Hacettepe UniversityRecruitingSedation | Target Controlled Infusion of Propofol | Intensive Care Unit SedationTurkey (Türkiye)
-
Istanbul University - CerrahpasaRecruitingAtrial Fibrillation | Deep Sedation | Electric CountershockTurkey (Türkiye)
-
Hopital FochCompleted
-
Stanford UniversityTiny Blue Dot FoundationEnrolling by invitationHealthy VolunteersUnited States
-
Istanbul UniversityRecruitingTotal Intravenous Anesthesia | Spinal (Fusion) Surgery | Target Controlled Infusion of Propofol | BIS-EEG | Anesthesia Depth MonitoringTurkey (Türkiye)
-
Konkuk University Medical CenterCompletedCoronary Artery Disease | Valvular Heart DiseaseKorea, Republic of
-
Marmara University Pendik Training and Research...RecruitingPediatric Anesthesia | Postoperative Agitations in Pediatric Patients | Postoperative Nausea and Vomiting (PONV) | Emergence Delirium in Pediatric AnesthesiaTurkey (Türkiye)